Related Experiment Video
Updated: Nov 14, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.1K
Advances in Insulin Pump Infusion Sets Symposium Report.
Jennifer Y Zhang1, Trisha Shang1, Sarnath Chattaraj2
1Diabetes Technology Society, Burlingame, CA, USA.
Journal of Diabetes Science and Technology
|March 11, 2021
Summary
Continuous subcutaneous insulin infusion (CSII) sets are crucial for diabetes management but lack recent technological advancements. Experts discussed patient burden, extended wear, and future directions for insulin infusion set development.
Area of Science:
- Diabetes Technology
- Endocrinology
- Biomedical Engineering
Background:
- Continuous subcutaneous insulin infusion (CSII) is a key method for glycemic control in diabetes.
- Insulin infusion sets (IIS) deliver insulin from the pump to the body via a cannula.
- Despite CSII's growing use, IIS technology has lagged behind advancements in insulin pumps and pharmacokinetics.
Purpose of the Study:
- To review recent developments in insulin infusion set (IIS) technology.
- To discuss future directions and innovations in IIS development.
- To address challenges and patient burden associated with current IIS.
Main Methods:
- A virtual symposium hosted by the Diabetes Technology Society on December 1, 2020.
- Presentations by experts from manufacturers (Medtronic, ConvaTec), academia (Stanford University), and clinical centers (Steno Diabetes Center Copenhagen).
- Discussions focused on patient burden, extended wear technology, and future IIS development.
Main Results:
- Identified a need for innovation in insulin infusion set (IIS) technology.
- Highlighted patient burden as a significant factor in IIS design and use.
- Explored potential for extended wear technologies to improve user experience and adherence.
- Outlined future research and development directions for next-generation IIS.
Conclusions:
- Advancements in insulin infusion set (IIS) technology are needed to match progress in other areas of diabetes management.
- Future IIS development should prioritize reducing patient burden and exploring extended wear capabilities.
- Collaboration between manufacturers, researchers, and clinicians is essential for driving IIS innovation.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
385
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
385
01:16Insulin: Dosing Regimen and Adverse Effects
391
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
391
01:25Insulin: Biosynthesis, Chemistry, and Preparation
807
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
807
01:28Insulin: The Receptor and Signaling Pathways
1.9K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.9K